한국어
English
日本語
中文(简体)
Banplitaz Tablet 17.7 mg (Quizartinib Hydrochloride)
20mg
Tablet · Prescription medication
Daichi Sankyo Korea Co., Ltd.
Quizartinib hydrochloride is an active ingredient used in the treatment of acute myeloid leukemia.
MFDS ingredient code M286105
Quizartinib hydrochloride is an active ingredient used in the treatment of acute myeloid leukemia with specific genetic mutations. This ingredient is developed as a targeted therapy that inhibits the growth and division of cancer cells. It is mainly utilized in the treatment of patients with blood cancers.
Quizartinib hydrochloride blocks the activity of specific proteins within cancer cells, preventing the signaling that leads to cancer cell proliferation. This inhibits the growth of cancer cells and induces apoptosis. It relatively has less impact on normal cells.
Approved uses differ by product. Check each product's information for its actual use.
Quizartinib hydrochloride is distinguished from other anticancer agents by targeting FLT3 gene mutations. This targeted therapy focuses on reducing side effects and enhancing therapeutic efficacy. Unlike conventional chemotherapy, it selectively attacks specific cancer cells.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.
